|
1
|
Naito S, Yamamoto N, Takayama T, Muramoto
M, Shinohara N, Nishiyama K, Takahashi A, Maruyama R, Saika T,
Hoshi S, et al: Prognosis of Japanese metastatic renal cell
carcinoma patients in the cytokine era: A cooperative group report
of 1463 patients. Eur Urol. 57:317–326. 2010. View Article : Google Scholar
|
|
2
|
Wang LL: Biology of osteogenic sarcoma.
Cancer J. 11:294–305. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shor AC, Keschman EA, Lee FY, Muro-Cacho
C, Letson GD, Trent JC, Pledger WJ and Jove R: Dasatinib inhibits
migration and invasion in diverse human sarcoma cell lines and
induces apoptosis in bone sarcoma cells dependent on SRC kinase for
survival. Cancer Res. 67:2800–2808. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Assouad J, Petkova B, Berna P, Dujon A,
Foucault C and Riquet M: Renal cell carcinoma lung metastases
surgery: Pathologic findings and prognostic factors. Ann Thorac
Surg. 84:1114–1120. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ono R, Taki T, Taketani T, Taniwaki M,
Kobayashi H and Hayashi Y: LCX, leukemia-associated protein with a
CXXC domain, is fused to MLL in acute myeloid leukemia with
trilineage dysplasia having t (10;11) (q22;q23). Cancer Res.
62:4075–4080. 2002.PubMed/NCBI
|
|
6
|
Ito S, D'Alessio AC, Taranova OV, Hong K,
Sowers LC and Zhang Y: Role of Tet proteins in 5mC to 5hmC
conversion, ES-cell self-renewal and inner cell mass specification.
Nature. 466:1129–1133. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tahiliani M, Koh KP, Shen Y, Pastor WA,
Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L, et
al: Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in
mammalian DNA by MLL partner TET1. Science. 324:930–935. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Guo JU, Su Y, Zhong C, Ming GL and Song H:
Hydroxylation of 5-methylcytosine by TET1 promotes active DNA
demethylation in the adult brain. Cell. 145:423–434. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Haffner MC, Chaux A, Meeker AK, Esopi DM,
Gerber J, Pellakuru LG, Toubaji A, Argani P, Iacobuzio-Donahue C,
Nelson WG, et al: Global 5-hydroxymethylcytosine content is
significantly reduced in tissue stem/progenitor cell compartments
and in human cancers. Oncotarget. 2:627–637. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang H, Liu Y, Bai F, Zhang JY, Ma SH, Liu
J, Xu ZD, Zhu HG, Ling ZQ, Ye D, et al: Tumor development is
associated with decrease of TET gene expression and
5-methylcytosine hydroxylation. Oncogene. 32:663–669. 2013.
View Article : Google Scholar
|
|
11
|
Lian CG, Xu Y, Ceol C, Wu F, Larson A,
Dresser K, Xu W, Tan L, Hu Y, Zhan Q, et al: Loss of
5-hydroxymethylcytosine is an epigenetic hallmark of melanoma.
Cell. 150:1135–1146. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fu HL, Ma Y, Lu LG, Hou P, Li BJ, Jin WL
and Cui DX: TET1 Exerts its tumor suppressor function by
interacting with p53-EZH2 pathway in gastric cancer. J Biomed
Nanotechnol. 10:1217–1230. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hsu CH, Peng KL, Kang ML, Chen YR, Yang
YC, Tsai CH, Chu CS, Jeng YM, Chen YT, Lin FM, et al: TET1
suppresses cancer invasion by activating the tissue inhibitors of
metalloproteinases. Cell Rep. 2:568–579. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sun M, Song CX, Huang H, Frankenberger CA,
Sankarasharma D, Gomes S, Chen P, Chen J, Chada KK, He C, et al:
HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth
and metastasis. Proc Natl Acad Sci USA. 110:9920–9925. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hou P, Ji M, Yang B, Chen Z, Qiu J, Shi X
and Lu Z: Quantitative analysis of promoter hypermethylation in
multiple genes in osteosarcoma. Cancer. 106:1602–1609. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Oh JH, Kim HS, Kim HH, Kim WH and Lee SH:
Aberrant methylation of p14ARF gene correlates with poor survival
in osteosarcoma. Clin Orthop Relat Res. 442:216–222. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Frycz BA, Murawa D, Borejsza-Wysocki M,
Marciniak R, Murawa P, Drews M, Kołodziejczak A, Tomela K and
Jagodziński PP: Decreased expression of ten-eleven translocation 1
protein is associated with some clinicopathological features in
gastric cancer. Biomed Pharmacother. 68:209–212. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sun M, Song CX, Huang H, Frankenberger CA,
Sankarasharma D, Gomes S, Chen P, Chen J, Chada KK, He C, et al:
HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth
and metastasis. Proc Natl Acad Sci. 110:9920–9925. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ivanov M, Barragan I and Ingelman-Sundberg
M: Epigenetic mechanisms of importance for drug treatment. Trends
Pharmacol Sci. 35:384–396. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jones PA and Laird PW: Cancer epigenetics
comes of age. Nat Genet. 21:163–167. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ito S, Shen L, Dai Q, Wu SC, Collins LB,
Swenberg JA, He C and Zhang Y: Tet proteins can convert
5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine.
Science. 333:1300–1303. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hou P, Ji M, Yang B, Chen Z, Qiu J, Shi X
and Lu Z: Quantitative analysis of promoter hypermethylation in
multiple genes in osteosarcoma. Cancer. 106:1602–1609. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rao-Bindal K and Kleinerman ES: Epigenetic
regulation of apoptosis and cell cycle in osteosarcoma. Sarcoma.
2011:6794572011. View Article : Google Scholar : PubMed/NCBI
|
